Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)

NCT01145495 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01145495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01145495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2010
Completion date
January 15, 2022
Enrollment
66 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage ii grade 1 contiguous follicular lymphoma, ann arbor stage ii grade 1 non-contiguous follicular lymphoma, ann arbor stage ii grade 2 contiguous follicular lymphoma, ann arbor stage ii grade 2 non-contiguous follicular lymphoma, ann arbor stage ii grade 3 contiguous follicular lymphoma, ann arbor stage ii grade 3 non-contiguous follicular lymphoma, ann arbor stage iii grade 1 follicular lymphoma, ann arbor stage iii grade 2 follicular lymphoma, ann arbor stage iii grade 3 follicular lymphoma, ann arbor stage iv grade 1 follicular lymphoma, ann arbor stage iv grade 2 follicular lymphoma, ann arbor stage iv grade 3 follicular lymphoma